Remus Pharmaceuticals Limited (NSE:REMUS)

Market Cap	3.98B
Revenue (ttm)	6.20B
Net Income (ttm)	290.70M
Shares Out	5.83M
EPS (ttm)	49.34
PE Ratio	13.85
Forward PE	n/a
Dividend	1.50 (0.22%)
Ex-Dividend Date	Sep 18, 2025

Volume	700
Average Volume	5,435
Open	670.00
Previous Close	684.40
Day's Range	660.05 - 683.50
52-Week Range	636.10 - 1,385.00
Beta	0.21
RSI	24.11
Earnings Date	Nov 10, 2025

About Remus Pharmaceuticals

Remus Pharmaceuticals Limited engages in the marketing, trading, and distribution of pharmaceuticals products and allied products in India and internationally. It is involved in trading of active pharmaceutical ingredient, as well as provides technical and consultancy services to various distributors and contract manufacturing services. The company offers tablet, hard and soft gelatine capsules, liquid and lyophilized injections, as well as pre-filled syringe, infusions, inhalers, nebulizers, nasal sprays and solutions, eye drops, creams, gels,...

• Industry: Drugs, Drug Proprietaries, and Druggists' Sundries
• Founded: 2015
• Employees: 68
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: REMUS

Financial Performance

In 2024, Remus Pharmaceuticals's revenue was 6.20 billion, an increase of 191.33% compared to the previous year's 2.13 billion. Earnings were 290.70 million, an increase of 41.67%.